J Oyee

1.3k citations

38 papers · 887 indexed · h-index 17

Impact in

Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism
Virology top 10%
- HIV Research and Treatment

Papers in ⓘ

Oncology 12
- Cancer Treatment and Pharmacology 4
Pulmonary and Respiratory Medicine 11
- Lung Cancer Treatments and Mutations 9
- Lung Cancer Diagnosis and Treatment 6

Co-authors: Angela Boland (19 shared papers)Rumona Dickson (13 shared papers)A Bagust (13 shared papers)Y Dündar (17 shared papers)Tamara Brown (6 shared papers)Paula Williamson (3 shared papers)Munir Pirmohamed (2 shared papers)Richard J. Fitzgerald (1 shared paper)
Journals: Health Technology Assessment (11 papers)Open Forum Infectious Diseases (4 papers)PharmacoEconomics (3 papers)Clinical Infectious Diseases (1 paper)British Journal of Cancer (1 paper)
Partner nations: United Kingdom Spain United States

In The Last Decade

J Oyee

32 papers receiving 864 citations

Peers

Countries citing papers authored by J Oyee

Since Specialization

Citations

This map shows the geographic impact of J Oyee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Oyee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Oyee more than expected).

Fields of papers citing papers by J Oyee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Oyee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Oyee. The network helps show where J Oyee may publish in the future.

Co-authors

The 25 scholars most cited alongside J Oyee, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J Oyee Line = papers co-authored together J Oyee links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis PLoS ONE ·Andrea Jorgensen, Richard J. Fitzgerald, J Oyee, Munir Pirmohamed, Paula Williamson	2012	122
2	A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer Thorax ·Gerlinde Pilkington, Angela Boland, Tamara Brown, J Oyee, A Bagust, Rumona Dickson	2015	89
3	Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial Clinical Infectious Diseases ·Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng, Olayemi Osiyemi, Carlos Galera, Laurent Hocqueloux, Franco Maggiolo, Olaf Degen, Stephen Taylor, Elizabeth A. Blair, Choy Man, Brian Wynne, J Oyee, Mark Underwood, Lloyd Curtis, Gilda Bontempo, Jean van Wyk	2022	80
4	A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy. Health Technology Assessment ·Jo Hockenhull, Mariam Elremeli, Mary Gemma Cherry, James Mahon, Minchun Lai, Jacqueline E. Darroch, J Oyee, Angela Boland, Rumona Dickson, Y Dündar, Robert Boyle	2012	54
5	Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation Health Technology Assessment ·Tamara Brown, Gerlinde Pilkington, A Bagust, Angela Boland, J Oyee, Catrin Tudur Smith, M Blundell, Mei‐Shu Lai, C Martin Saborido, J Greenhalgh, Y Dündar, Rumona Dickson	2013	51
6	Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis Health Technology Assessment ·Nigel Fleeman, A Bagust, Angela Boland, R Dickson, Y Dündar, May Moonan, J Oyee, M Blundell, Hugh L. Davis, Anne Armstrong, Nicky Thorp	2011	50
7	Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer Health Technology Assessment ·Tamara Brown, Angela Boland, A Bagust, J Oyee, Jo Hockenhull, Y Dündar, Rumona Dickson, VS Ramani, C Proudlove	2010	50
8	The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technology Assessment ·Nigel Fleeman, C Martin Saborido, Katherine Payne, Angela Boland, R Dickson, Y Dündar, Ana Fernández‐Santander, Sacha J. Howell, William G. Newman, J Oyee, T Walley	2011	41
9	Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy PharmacoEconomics ·Rumona Dickson, A Bagust, Angela Boland, Michaela Blundell, Helen Davis, Y Dündar, Juliet Hockenhull, C Martin Saborido, J Oyee, V. S. Ramani	2011	40
10	Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom Current Medical Research and Opinion ·Jonathan Karnon, Keith Tolley, J Oyee, K. Jewitt, D. Ossa, R. Akehurst	2008	40
11	Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review Health Technology Assessment ·Tamara Brown, Gerlinde Pilkington, Angela Boland, J Oyee, Catrin Tudur Smith, Y Dündar, Elaine M. Richards, Ruonan Yang, Rumona Dickson	2013	38
12	Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials Open Forum Infectious Diseases ·Cassandra Nan, Mark S. Shaefer, Rimgaile Urbaityte, J Oyee, Judy Hopking, Leigh Ragone, Teodora Perger, B. Ronald Win, H. Vangerow, Cynthia McCoig, Vani Vannappagari	2018	29
13	Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis Health Technology Assessment ·J Greenhalgh, A Bagust, Angela Boland, C Martin Saborido, J Oyee, M Blundell, Y Dündar, Rumona Dickson, C Proudlove, Michael Fisher	2011	25
14	Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma PharmacoEconomics ·J Greenhalgh, A Bagust, Angela Boland, Michaela Blundell, J Oyee, Sophie Beale, Y Dündar, Juliet Hockenhull, Chris Proudlove, Patrick Chu	2013	24
15	Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model Breast Cancer Research and Treatment ·Michael P. Lux, Michael Hartmann, Christian Jackisch, Guenther Raab, Andreas Schneeweiß, K. Possinger, J Oyee, Nadia Harbeck	2009	22
16	Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer Health Technology Assessment ·J Greenhalgh, C McLeod, A Bagust, Angela Boland, Nigel Fleeman, Y Dündar, J Oyee, Rumona Dickson, Helen Davis, J Green, Edward McKenna, M Pearson	2010	16
17	Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B5701 Screening as a Risk‐Mitigation Measure Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy* ·Chris Stainsby, Teodora Perger, Vani Vannappagari, Karam Mounzer, Ricky K Hsu, Cassidy Henegar, J Oyee, Rimgaile Urbaityte, Charlotte Lane, Lindsay M. Carter, Gary E. Pakes, Mark S. Shaefer	2018	16
18	Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer British Journal of Cancer ·David Cameron, D. Ross Camidge, J Oyee, M Hirsch	2008	15
19	Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer Health Technology Assessment ·Tamara Brown, Angela Boland, A Bagust, J Oyee, Jo Hockenhull, Y Dündar, Rumona Dickson, VS Ramani, C Proudlove	2010	15
20	Análisis de coste-efectividad de la vacunación frente al virus del papiloma humano tipos 6, 11, 16 y 18 en España Vacunas ·Nathalie Largeron, V. Rémy, J Oyee, M. Martin, Javier Cortés, L. Olmos	2008	15

About J Oyee

J Oyee is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Infectious Diseases, Cancer Research and Virology, having authored 38 papers that have together received 887 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (6 papers), Lung Cancer Diagnosis and Treatment (6 papers), Breast Cancer Treatment Studies (5 papers), Cancer Treatment and Pharmacology (4 papers), HIV/AIDS Research and Interventions (4 papers) and HIV-related health complications and treatments (4 papers). The work is most often cited by research in Pharmacology (139 citations), Virology (75 citations), Oncology (266 citations), Emergency Medicine (66 citations) and Infectious Diseases (117 citations). J Oyee has collaborated with scholars based in United Kingdom, Spain and United States. Frequent co-authors include Angela Boland, Rumona Dickson, A Bagust, Y Dündar, Tamara Brown, Paula Williamson, Munir Pirmohamed, Richard J. Fitzgerald, Andrea Jorgensen and Gerlinde Pilkington. Their work appears in journals such as Health Technology Assessment, Open Forum Infectious Diseases, PharmacoEconomics, Clinical Infectious Diseases and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact